<DOC>
	<DOC>NCT02405338</DOC>
	<brief_summary>This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients. Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.</brief_summary>
	<brief_title>DC Vaccination for Post-remission Therapy in AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis of Acute Myeloid Leukemia (AML) Age 18 75 years Morphologic remission (CR) with or without hematological recovery (CRi) following induction chemotherapy WT1 with or without PRAME positivity by qPCR Negative pregnancy test in women of childbearing potential (within 7 days before the first vaccination). Women of childbearing potential and sexually active male participants must use reliable methods of contraception during the whole treatment period and 3 months after the last trial drug dose Negative HIV 1 and 2 test, Hepatitis B and C test and negative Syphilis test at screening Informed consent signed prior to any trial related activities Patients suitable for allogeneic stem cell transplantation AML M3 (acute promyelocytic leukemia) Patients not in complete remission (CR or CRi), bone marrow blast count â‰¥ 5 % Active immunodeficiency syndromes Concurrent active second malignancy other than nonmelanoma skin cancers Clinically relevant autoimmune disease Prior immunotherapy Severe organ dysfunction precluding the apheresis procedure: Creatinine &gt; 200 mmol/l Bilirubin, ALAT and ASAT &gt; 3 x upper normal limit Respiratory insufficiency with pO2 &lt; 60 mmHg Clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure &gt; grade II NYHA Recent cerebral hemorrhage Known allergies to substances used in the generation of DCs Other severe acute or chronic medical psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or the administration of the investigational product Use of corticosteroids Active CMV infection (Antibodypositivity due to previous, now inactive infection is accepted) Inability to comply with the trial protocol Participation in other clinical trials that, according to the investigator's discretion, may interfere with this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AML</keyword>
</DOC>